AI Summary
This cohort study compares the effectiveness of rituximab and ocrelizumab in preventing relapses and disability in patients with relapsing-remitting multiple sclerosis.
This cohort study investigates if rituximab is noninferior to ocrelizumab in the prevention of relapses and disability in patients with relapsing-remitting multiple sclerosis.